Hamlet - Ghosts Speech - Act 1 Essay Example for Free

Hamlet Ghosts Speech Act 1 Essay In the beginning of the play, the reader is introduced to the disorder in Denmark, a prevalent motif. The mysterious death of the king spurred the disorder, and the prospect of revenge was magnified by the supposed appearance of the late King Hamlet’s ghost. The ghost’s appearance and subsequent speech intensify the disorder by validating the reader’s suspicion of Claudius as a murderer and an incestuous, adulterous serpent. Hamlet is torn by this revelation, and responds with justified drama. Thus far Hamlet had a few reasons to hate Claudius; the ghost’s message emboldened everything he had suspected and even added to it. Previously in Act One, Hamlet had criticized Claudius for a few major grievances: for being opportunist upon the death of his father by marrying his newly widowed mother in order to seize the throne instead of Hamlet, for not properly mourning the king by waiting just a month to take his wife, and for acting like an animal by behaving in an incestuous and lustful manner. By playing on many of the same metaphors as Hamlet and bringing forth new claims too, the ghost- whose word the reader takes as truth- bolsters Hamlet’s claims. In the ghost’s rhetoric, Claudius is an unnatural, murderous â€Å"serpent†.(sc. 5 ln. 43) As a â€Å"fat weed,† his parasitic nature is apparent and matches Hamlet’s assessment of the situation as an â€Å"unweeded garden.† (sc. 5 ln. 39) (sc. 2 ln. 139) Later, the ghost goes on to describe â€Å"lewdness† courting â€Å"virtue† in Claudius’ despicable new relationship.(sc. 5 ln. 60-1) To Hamlet and the ghost, the new union is an embodiment of evil though it holds an honorable, royal position. The royal bed is now a couch for luxury and incest. (sc 5. ln.89-90) The queen has been corrupted by â€Å"wicked wit and gifts† and succumbed by what almost sounds like magic. (sc. 5 ln. 51) This too plays on the motif of unnatural existence in â€Å"Hamlet† as exemplified by the ghost. The ghost refers to public opinion as â€Å"the ear of Denmark.† (sc.5 ln.43) By misleading this one representative ear, the entire country has been misled.  The ghost then furthers the ear imagery by describing how he was personally poisoned through his ear. This deception perpetrated by the current king adds to the sense of unrest. The late Hamlet was â€Å"sleeping within (his) orchard,† an emphatically innocent action, as the juice was poured into his ear and coursed through his body like quicksilver. (sc. 5 ln. 66) The poison â€Å"tetter(ed)†¦about†¦with vile and loathsome crust.† (sc. 5 ln.78-79) This vivid and gory description adds to the sense of decay and discord. As Marcellus put it, â€Å"something is rotten in the state of Denmark.† (sc.4 ln. 100) Then the ghost talks about how that napping time was his â€Å"secure hour.† (sc.5 ln. 68) This describes the feeling of routine that once existed in the kingdom. Now time is cursed and nothing is happens in a proper time because of Claudius’ unnatural murder. The senses of touch and sight are very important in this speech. The ghost carefully describes how things looked and felt to actualize his feelings to Hamlet and the reader. When describing the queen, he uses a prickly set of descriptive words. She isn’t just part of a cursed union, she has â€Å"thorns that in her bosom lodge to prick and sting her,† by some heavenly will. (sc, 5 ln. 94-5) Additionally, the description of the poisoning is graphic to make it personal and real for Hamlet.

Calculating Free Fall Acceleration

Calculating Free Fall Acceleration Introduction A research by Heckert (2010) shows in 1600s, the famous physicist Galileo . Galilei found the swinging motion of a large chandelier in the Pisa cathedral. He began to seriously analyse the chandelier, and recorded the time the light took to swing. In the 16th century, there was no stopwatch so that Galileo timed the swing by pulse. In addition, he was the first European to really study this phenomenon and he discovered that their regularity could be used for calculate the local gravity. For Galileo his pendulum was the light but generally speaking a pendulum can be defined as a body suspended from a fixed point which swing freely by the motion of gravity and momentum. It is used to regulate the movements of clockwork and other machinery. In its simplest form and avoiding the math there are three parts to the basic laws of a pendulum. First the time for each oscillation is depending on the length of the strings. In addition, mass of the bob does not affect the motion at all. Second, a pendulums horizontal speed is the same as the vertical speed would be, if the bob had fallen from its highest point. Thirdly, the square of period of the bob is inversely proportional to free fall acceleration and the square of period of the body is proportional to length of the pendulum The background definition and the laws of a pendulum can be used to calculate the free fall acceleration. Using a simple gravity pendulum like Galileos Pendulum System, I would like to show how to find the best ways in order to test free fall acceleration. Methods 1. Experiment equipment: Protractor Steel Bob Stopwatch Vernier Caliper Iron Support Stand Meter Ruler Inelastic String 2. Apparatus setup Figure1-1 Figure1-1 shows that iron support stand was put beside edge of test desk in case the height of stand was shorter than the length of test string. Next, the steel ball was hung by an inelastic string and the iron support stand was used to support the weight of steel ball. Last, the clip was clamped to the string in order to keep a constant length. At the same time, the bob swing in a vertical surface which parallels the stand. 3. Procedures First of all, the simple pendulum was made up by hanging a bob from the top of stand and the bob was released in a constant height, then protractor was used to control the degree between 5 and 15 to normal line. Secondly, pendulum would begin to oscillate in vertical surface in a regular action, and then the stop watch was used to record the time of each swing. Finally the most important data which describes this oscillation is period and we did different types of test by different length of string, like 30cm, 45 cm, 60 cm, 75 cm, 90cm, 105 cm, and 120 cm. Results Table of result Experiment times Length of string (cm) Trials: 1 Trials: 2 Total Average period Oscillationtimes Average period of each swing T2 (second square) Time taken for one complete Oscillation(seconds) 1 30cm 56.60s 56.50s 56.55s 50 times 1.13s 1.28s2 2 45 cm 68.60s 68.50s 68.55s 50 times 1.37s 1.88 s2 3 60 cm 79.00s 78.90s 79.00s 50 times 1.58s 2.50 s2 4 75 cm 87.60s 87.90s 87.75s 50 times 1.76s 3.08 s2 5 90 cm 96.05s 96.00s 96.05s 50 times 1.92s 3.69 s2 6 105 cm 104.00s 104.00s 104.00s 50 times 2.08s 4.33 s2 7 120 cm 110.50s 111.00s 110.75s 50 times 2.22s 4.91 s2 Table-1.1 Table-1.1 shows the data of 7 experiments using different length of string and how the data changed, as the length of string was increased; the period of each oscillation was increase as well. L is the distance from the frame of the stand to the center of the mass; the length includes the radius of ball. The period of oscillation is the time required for the pendulum to complete one swing. For one complete swing, the steel ball must move from the left to the right and back to the left. T2 can be understood as the square of the period of oscillation, the equation below shows how T2 was calculated. Square both sides: T2= 4 Ãâ€" Ï€2 Ãâ€" (L/g) T2 = L Ãâ€" (4 Ãâ€" Ï€2 à · g) Multiply both sides by g g Ãâ€" T2 = 4 Ãâ€" Ï€2 Ãâ€" L Divide both sides by T2 Discussion and Analysis The results of experiment show the relation between T2 and length of string. To turn to discuss the results it is important to understand some key ideas, there are controlled variable, experimental variable, error and uncertainty. Firstly, according to Science Buddies(2009) said that a controlled variable can be defined as the factor which is unchanged or kept constant to prevent its effects or error on the outcome. It was verified the behavior of the relationship between independent and dependent variables. The factors which can be regarded as controlled variable were steel ball, oscillation times; the angle of each swing and the height when the steel ball was released. An answer from wiki (2009) the definition of experimental variables is the variable whose values are independent of changes in the values of other variables. Experimental variable in this experiment is the length of string. According to dictionary the error can be defined as a deviation from accuracy or correctness. And the uncertainty means that the lack of certainty, a state of having limited knowledge so that it is impossible to exactly describe existing phenomenon or future outcome confidently.Errors were caused by any individual who could be affected by many factors. Such as before we measure the length of string, we need to measure the radius of ball by vernier caliper in case the string is shorter than actual length. Secondly, we need to take care of how much oscillation times we did. Thirdly, we need to keep the pendulum swing in a same surface in case the extra energy was wasted. At last, taking more time measurements of experimental variable which is length of string may be more accurate average for each trial. Find two point from the graph A(x1, y1) B(x2, y2), use the formula (y2-y1)/(x2-x1) the result of gradient is 4.03. The table shows the results of free fall acceleration Gradient(T2/L) 4.03 Calculate data in using formula G 9.79ms-2 Confines of Error 0.22% Table2-1 To summarize the weakness that is error and uncertainty and calculating the acceleration of gravity to within 5%, and table 2-1 shows that the experiment obeys the allowable confines. Confines of Error were calculated by the difference between actual gravity and what I got, and the values were divided by the actual values. Conclusion To sum up, the calculation of Galileo that free fall acceleration from the formula, this can infer the result of free fall acceleration. I need to compare the calculation of Galileo which free fall acceleration should be 9.81ms-2. In fact, a gravity pendulum is a complex machine, depending on a number of variables for which we are ready to adjust. In addition, firstly we try to understand the method that Galileo did in 1600s, and making a plan to have a complete the system. Then form the data I found some different values about gravity, and the factor to influence the values. The main factor is that the different length of string influence the period instead free fall acceleration, the period square and length have a constant ratio to calculated the acceleration. Turning to Dohrman, P (2009) it can be argued that the factors which influence the fact are length of the string, period of each cycle by using those two factors we can get the local gravity. All above those factors can influence the values of free fall acceleration, and we got the less number than actual values. I need to take care of them and have an improvement. For instance, first difficulty is that measuring the length is deciding where the centre of the bob is. The uncertainty in determining this measurement is probably about 1 mm. Secondly, the stopwatch measures to 50 of oscillation although the overall accuracy of the time measurements may be not certain. According toDohrman (2009) the human reaction time to start and stop the watch has a maximum range of 0.13 seconds and the average is0.7. Finally, 9.79ms-2 was calculated by the gradient and the formula in part of result.

The Indian Pharmaceutical Industry

The Indian Pharmaceutical Industry The Indian Pharmaceutical Industry today is in the front rank of Indias science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. A highly organized sector, the Indian Pharmaceutical Industry is estimated to be worth, $4.5 billion, growing at about 8 to 9 percent annually. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. The number of purely Indian pharmaceutical companies is fairly low. Indian pharmaceutical industry is mainly operated and controlled by dominant foreign companies having subsidiaries in India due to availability of cheap labour in India at lowest cost. Most pharmaceutical companies operating in India, even the multinationals, employ Indians almost exclusively from the lowest ranks to high level management. Mirroring the social structure, firms are very hierarchical. Homegrown pharmaceuticals, like many other businesses in India, are often a mix of public and private enterprise. Although many of these companies are publicly owned, leadership is passed from father to son and the founding family holds a majority share. In 2002, over 20,000 registered drug manufacturers in India sold $9 billion worth of formulations and bulk drugs. 85% of these formulations were sold in India while over 60% of the bulk drugs were exported, mostly to the United States and Russia. Most of the players in the Indian market are small-to-medium enterprises. It has been estimated that 250 of the largest companies control 70% of the Indian market. The 1970 Patent Act., made the multinational companies to represent only 35% of the market, down from 70%, thirty years ago. In terms of the global market, India currently holds a modest 1-2% share, but it has been growing at approximately 10% per year. India gained its foothold on the global scene with its innovatively engineered generic drugs and active pharmaceutical ingredients (API), and it is now seeking to become a major player in outsourced clinical research as well as contract manufacturing and research. There are 74 U.S. FDA-approved manufacturing facilities in India, more than in any other country outside the U.S, and in 2005, almost 20% of all Abbreviated New Drug Applications (ANDA) to the FDA were filed by Indian companies. Growths in other fields notwithstanding, generics are still a large part of the picture. As such, the Indian pharmaceutical industry has now become the third largest producer in the world and is poised to grow into an industry of $ 20 billion by 2015, from the current turnover of $ 12 billion. As a result, manufacturing expertise and efficiency were the only requirements to participate in this industry, creating low barriers of entry. The most critical challenge facing the global pharmaceutical industry today is the increasing cost of drug discovery and development and the increasing time to market. This is further compounded by: Impending patent expirations of blockbuster molecules Pricing pressures Low public opinion Challenges to intellectual property by increasingly aggressive generic companies. Re-importation pressures Medicare/Medicaid reform Increasing regulatory hurdles This scenario is forcing the multinational pharmaceutical companies (MNCs) to rethink their strategic options in order to exploit their core competencies across the globe. In this situation, India stands to a gain a lot because of its inherent advantages like stability, culture, cost, and educated workforce. This has led to increased alliances and collaborations as a result; the leading Indian pharmaceutical companies have become some of the most efficient manufacturing units in the world. In fact, India has the highest number of US FDA (Food and Drug Administration) certified manufacturing facilities outside USA. The overall phenomenal progress made by the industry in the last three decades has instilled a strong belief in the government and the pharmaceutical companies in India that the country has a competitive strength and it should be enhanced by suitable policy measures and firm specific actions with regards to export, innovation, strategic alliances and investment. The pharmaceutical policy 2002 echoes the same sentiments and has shifted focus of the policy from self reliance in drug manufacturing to the objective of enhancing global competitiveness. The introduction of policy says: The basic objectives of the governments policy relating to drug and pharmaceutical sector were enumerated in drug policy of 1986. These basic objectives still remain largely valid, however, the drug and the pharmaceutical industry in the country today faces new challenges on account of liberalization of the Indian economy the globalization of the world economy and on account of new obligations undertaken by India under the WTO agreements. These challenges require a change in current pharmaceutical policy and the need for new initiatives beyond those enumerated in drug policy 1986, as modified in 1994, so that policy inputs are directed more towards promoting accelerated growth of the pharmaceutical industry and towards making it more internationally competitive. The need for radically improving the policy framework for knowledge-based industry has also been acknowledged by the government. The Prime Ministers Advisory Council on Trade and Industry has made important recommendations regarding knowledge-based industry. The Pharmaceutical industry has been identified as one of the most important knowledge based industries in which India has a comparative advantage. THE GROWTH STAGE OF INDIAN PHARMACEUTICAL INDUSTRY SECTION-1 2.1 GROWTH STAGES OF INDIAN PHARMA INDUSTRY Bengal Chemicals Pharmaceuticals Limited (BCPL), established in 1901, is a Public Sector Undertaking (PSU) of the Government of India and is Indias first pharmaceutical company. The company was started by Prafulla Chandra Roy in Kolkata (then known as Calcutta) and has since manufactured such household Indian products as Hospitol, naphthalene balls, and Phenol. The company is headquartered in Kolkata and reported aggregated revenues of Rs 6,199 lakhs (US$ 138.2 million) in fiscal 2006. The Nascent industry, however, received setbacks in the post world war-II period as a result of new therapeutic developments in the western countries that triggered natural elimination of older drugs from market usage by newer drugs like sulpha ,antibiotics, vitamins, hormones, antihistamine, tranquilizers, psycho pharmacological substances etc. This culminated in the discontinuation of local production based on indigenous materials and forced the industry to import bulk drugs meant for processing them in to formulations and for selling in the domestic market. Figure- 2.1: stages of Growth of Indian Pharmaceutical Industry . Source: ISID Working Paper, 2006/05. The government started to encourage the growth of drug manufacturing by Indian companies in the early 1960s. In the post independence period, Indian pharmaceutical industry exhibited four stages of growth (see Figure 2.1 2.2). In the first stage during 1950s-60s, the industry was largely dominated by foreign enterprises and it continued to rely on imported bulk drugs notwithstanding its inclusion in the list of basic industries for plan targeting and monitoring. Foreign firms, enjoying a strong patent protection under the Patent and Design Act 1911, were averse to local production and mostly opted for imports from home country as working of the patent. Given the inadequate capabilities of the domestic sector to start local production of bulk drugs and hesitation of foreign firms to do so, the government decided to intervene through starting public sector enterprises. This led to the establishment of the Indian Drugs and Pharmaceuticals Ltd. (IDPL) plants at Rishikesh and Hyderabad in 1961 and the Hindustan Antibiotics at Pimpri, Pune, in 1954, to manufacture penicillin. The starting of the public sector enterprises has been an important feature in the evolution of the pharmaceutical industry as it assumed initiative roles in producing bulk drugs indigenously and led to significant knowledge spillovers on the private domestic sector. The second growth stage, of the industry took place in the 1970s. The enactment of the Indian Patent Act (IPA) 1970 and the New Drug Policy (NDP) 1978 during this stage are important milestones in the history of the pharmaceutical industry in India. The IPA 1970 brought in a number of radical changes in the patent regime by reducing the scope of patenting to only processes and not pharmaceutical products and also for a short period of seven years from the earlier period of 16 years. It also recognizes compulsory licensing after three years of the patent. The enactment of the process patent contributed significantly to the local technological development via adaptation, reverse engineering and new process development. As there exits several ways to produce a drug, domestic companies innovated cost-effective processes and flooded the domestic market with cheap but quality drugs. This led to the steady rise of the domestic firms in the market place. The NDP 1978 has increased the pressure on foreign firms to manufacture bulk drugs locally and from the basic stage possible. Foreign ownership up to 74 per cent under the Foreign Exchange Regulation Act (FERA) 1973 was permitted to only those firms producing high technology drugs. Foreign firms that are simply producing formulations based on imported bulk drugs were required to start local production from the basic stage within a two year period. Otherwise were required to reduce their foreign ownership holding to 40 per cent. New foreign investments were to be permitted only when the production involves high technology bulk drugs and formulations thereon. In the third growth stage or phase of evolution Indian pharmaceutical industry developed modern technology for manufacturing of all dosage forms like tablets, capsules ,liquid ,oral, injectables etc.. This domestic industry based on large scale reverse engineering and process innovation achieved near self sufficiency in production of bulk drugs belonging to various major therapeutic groups resulting in lasting impact on competitive position of Indian pharmaceutical firms in national and international markets. During , 1980-90s ,Indian pharmaceutical industry had emerged as one of the most export oriented sectors in Indian pharmaceutical industry with more than 30% of the production being exported to the foreign market. In 1991, domestic firms contribute about 70-80% market share in case of bulk drugs and formulations respectively. The trade deficits of seventies had been replaced by trade surpluses of 1980s. (FIG-2.1). The fourth stage of evolution of industry during 1990s witnessed dramatic changes in the policy regime governing the pharmaceutical industry. The drug de-licensing, hundred percent foreign investments is permitted through automatic route and price control has been significantly reduced. One of the major factors that have increased the confidence of foreign multinationals looking for local opportunities in India is the adoption of a new product patent regime in January 2005, before that India had already carried out three amendments in march-1999, June2002 and April 2005, in the patent act of 1970 to bring to bring Indian patent regime in harmony with the WTO agreement on Trade Related Intellectual Property Rights (TRIPs). The third and the final one, known as the Patents (Amendment) Act, 2005 came into force on 4th April 2005 and introduced product patents in drugs, food and chemicals sectors. The term of patenting has also been increased to a 20 year period. The number of pharmaceut ical units has also increased to over 23,000 in 2002, further more Fig: 2.2: Growth phase of Indian pharmaceutical industry graph1 SOURCE: BEST PHARMA INDUSTRY REPORT-2011-INDIA The fifth stage is in progression (Fig.2.2), in which we are observing investment in innovation and research, with enactment of new IP laws and investments in biotechnology aided companies. There is promising growth in production of bulk drugs and formulations (Table: 2.1) from Rs 10 crores in 1947-48 to Rs 21100 crores in 2002-03 in formulations and almost nil in 1947-48 to Rs 5400 crores in 2002-03 in bulk drugs production. The drug industry also becomes capable to spent 497crores in 2002-2003 from almost nil in 1947-48 on research and development of new molecules. All in all Indian drug sales are expected to rise by an annual 8% to nearly $26.59 bn between 2006 and 2015 and further is the matter of wait and watch depending up on conditions prevailing in international and domestic markets. In the UNIDO-classification of developing countries, according to the state of art in the pharmaceutical sector India is ranked among the top and today India manufactures over 400 bulk drugs and around 60,000 formulations. 2.2 Drug industry-growth As shown in, Table: 2.1 and table2.2, depicts the growth progress in production of bulk drugs and finished formulations. India produces bulk drugs related to various therapeutic areas. Indian pharmaceutical industry, manufactures over 400 bulk drugs and roughly 60,000 finished medicines used in different formulations. 2.3 THE GROWTH SCENARIO IN CONTINEUM: Indias US $ 3.1 billion pharmaceutical industry is growing at the rate of 14 percent per year. It is one of the largest and most advanced among the developing countries. Domestic Demand The industry has enormous growth potential. Factors listed below determine the rising demand for pharmaceuticals. à ¢Ã¢â€š ¬Ã‚ ¢ The growing population of over of a billion à ¢Ã¢â€š ¬Ã‚ ¢ Increasing income à ¢Ã¢â€š ¬Ã‚ ¢ Demand for quality healthcare service à ¢Ã¢â€š ¬Ã‚ ¢ Changing lifestyle has led to change in disease patterns, and increased demand for new medicines to combat lifestyle related diseases. More than 85 per cent of the formulations produced in the country are sold in the domestic market, there has also been a record increase in consumption of drugs worldwide. India with its large population has recorded the therapeutic segmentation in healthcare market with changes in pattern of drug consumption in turn affecting its production.Fig:2.3 shows the percentage increase in sales in various therapeutic segments. India is largely self-sufficient in case of formulations. Some life saving, new generation under-patent formulations continue to be imported, especially by MNCs, which then market them in India. Overall, the size of the domestic formulations market is growing strongly at 10 percent per annum (Table, 2.4), with rs23047crores in 2006-07, from rs2350crores in 1987-88. Fig: 2.3: Percentage Increase therapeutic segments. SOURCE: ORG-MARG AUDIT-2011. Table 2.4 shows demand for drugs as per therapeutic segments, showing categories, for treatment of lifestyle-related diseases such as diabetes, cardiovascular diseases, and central nervous system are on the increase. Health scenario is also changing. There are around 700,000 new cases of cancer each year and total of around 2.5 million cases. It is estimated that there are around 40 million people in India with diabetes and the number is rising, 5.1 million HIV/AIDS patients, and 14 million tuberculosis cases. According to industry reports, while the Indian pharmaceutical industry witnessed a growth of 7 to 8 percent, the cardio-vascular segment recorded 15 to 17 percent growth and anti-diabetes segment of over 10-12 percent growth. So, with the increase in diseases and various ailments, consumption of medicines is on increase day by day (refer, Fig: 2.3). As per estimates, Over 20,000 registered pharmaceutical manufacturers exist in the country. The domestic pharmaceuticals industry output is expected to exceed Rs260 billion in the financial year 2002, which accounts for merely 1.3% of the global pharmaceutical sector. Of this, bulk drugs had accounted for Rs 54 bn (21%) and formulations, the remaining Rs 210 bn (79%). Table: 2.5, shows the 16.98% CAGR for bulk drugs amounting to rs17, 307.02 crores in 2009-10. 2.4 BULK INDUSTRY GROWTH EX-IM MARKET The export market growth has been one of the most outstanding features of the Indian pharmaceutical industry (Table-2.5). Negligible before the 1970s, exports started picking up after the abolition of product patents in 1972, accelerating in the 1980s and then growing rapidly since the mid-1990s. In recent years, exports have been increasing annually at more than 20%. The proportion of exports in net sales for the studied 120 companies was 44%. The export market was found to be larger than the domestic market not only for large companies, such as Ranbaxy (Now owned by Japanese Daichi Sankyo Corporation), Dr. Reddys or Cipla , but also for smaller companies such as Granules , Shilpa Medicare, Kopran , Transchem, and Pure Pharmaceutical etc. The period between 2000 and 2010 witnessed Indias top 10 drug companies growing in their sales turnovers, ranging between Rs 500-Rs 800 crores, to professionally-run MNC generics manufacturing companies with turnovers ranging from Rs 3,500 crores t o over Rs 7,000 crores. India is among the top 20 pharmaceutical exporters world-wide. Most of these exporting firms earlier dependent on bulk drug supplies, small exports to unregulated markets in Africa and Asia and formulation sales in the domestic market, the last 10 years saw them aggressively tapping regulated markets of the US and Europe and penetrating into newer and emerging market Exports Over 60 per cent of Indias bulk drug production is exported. Indias pharmaceutical exports are to the tune of Rs 87 billion, of which formulations contribute nearly 55 per cent and the rest 45 per cent comes from bulk drugs. In financial year 2005, exports grew by 21 per cent. Domestic pharmaceutical export, growing at 30 per cent per annum, touched a new height of US $ 4.8 billion in the financial year 2006-07. The years exports will push the drug sectors contribution to Indias Forex earnings to 7.75 per cent from the current 5 per cent. The growth in drug exports, despite the pressing generic competition in the global markets, is attributed to increased Abbreviated New Drug Applications (ANDAs) approvals in the US market and contribution from unconventional markets in Latin America, Australia and the emerging markets in the Middle East and African Region. The formulations and exports are largely to developing nations in CIS, South East Asia, Africa and Latin America. In the last 3 years generic exports to developed countries have picked up.In the coming years, opening up of US generics market and anti AIDS market in Africa will boost exports. Indias pharmaceutical sector has seen unprecedented changes in the past decades ensuing for a remarkable growth in its exports (pharmaceutical exports occupy a share of 4.4% to 5.2% of Indias total exports over the last 6 years) and exports grew at a CAGR of around 22% in the 6 year period of 2004-05 to 2009-10( Fig:2.4). Indias growth story in itself vindicates its potential; it had a $ 333.33m turnover in 1980 to around $22.30 bn. by 2010-11 FIG: 2.4 PHARMA EXPORT TOTAL EXPORT SHARE pharmaceutical industry in the country today faces new challenges on account of LIbralisation of the Indian economy graph2.JPG SOURCE: Indian pharmaceutical export [emailprotected] 2.5 Revenue from Export As earlier discussed India accounts for less than two per cent of the world market for pharmaceuticals, with an estimated market value of US $ 10.4 billion in 2007 at consumer prices, or around US $ 9 per capita but has the potential to reach more than 2% by 2020. India currently represents just US $ 6 billion of the $ 550 billion global pharmaceutical industry but its share is increasing at 10 percent a year, compared to 7 percent annual growth for the world market overall. Also, while the Indian sector represents just 8 percent of the global industry total by volume, putting it in fourth place worldwide, it accounts for 13 percent by value, and its drug exports have been growing 30 percent annually. Cipla, Nicholas Piramal, Ranbaxy, Zydus Cadila, Dr. Reddys are the few Indian pharmaceutical companies, which are known at the global level due to their quality products. The Indian market for over-the-counter medicines (OTCs) is worth about $940 million and is growing 20 percent a year, or double the rate for prescription medicines. The industrys exports were worth more than $3.75 billion in 2004-05 and they have been growing at a compound annual rate of 22.7 percent over the last few years, according to the governments draft National pharmaceuticals Policy for 2006, published in January 2006. The Policy estimates that, by the year 2010, the industry has the potential to achieve $22.40 billion in formulations, with bulk drug production going up from $1.79 billion to $5.60 billion. Import Imports have registered a CAGR of only 2 per cent in the past 5 years. Import of bulk drugs have slowed down in the recent years as per DGIC reported data in the year 2010-11. The value of export was Rs 10,937 Crores, recording a declining growth of 9.82% as compared to 15.15% in 2009-10. The situation is advantageous and good sign, as the industry is becoming self reliant in production and less dependent on foreign markets. Based on the retrospective data, USA, Germany, Russia, UK, China, Brazil, Canada, South Africa, Nigeria, Netherlands, Spain, Turkey, Ukraine, Vietnam, Israel, Italy, Mexico, UAE, Singapore, Iran had been potential importers of Indian Drugs. Countries like South Africa, Israel, Turkey, Kenya, Singapore, UK, China, Russia, Italy and Vietnam etc. have been identified to be potential prospective markets with high growth rates of imports from India. Africa, Latin America, ASEAN and CIS countries with huge demands deem them to be put in the category of focus countries as these are the emerging markets and have a huge potential with day in day out incremental growth rates of per capita drugs consumptions supported by treaties like SAFTA (with SAARC), treaties with GCC, EU, Japan, Korea etc. As shown in table: 2.10, based on such estimates, it has been predicted that the 17% export growth of Rs 248,000 crores would be achieved in 2019-20 with a domestic growth of 22% amounting to Rs 233,000c rores. Section-II CROSS BORDER ACQUISITIONS IN INDIAN PHARMACEUTICAL INDUSTRY 2.6 INDIAN PHARMACEUTICAL SECTOR CROSS-BORDER ACQUISITION The health-care costs are rising world-wide. Leading companies across the world are merging. Strategic alliances and collaborations are taking place in order to meet the increasing RD budgetary requirement that exceed billion dollars each for many leading global pharmaceutical players. Indian Drug manufacturers are pursuing foreign acquisitions due to their need to: Improve global competitiveness Move up the value chain Create and enter new markets Increase their product offering Acquire assets (including research and contract manufacturing firms, in order to further boost their outsourcing capabilities) and new products Consolidate their market shares Compensate for continued sluggishness in their home market. Often there is a significant overlap of expenditure in creating manufacturing assets or investing in RD either in generics or in basic research resulting into wastages at national level. Consequently corporate have indulged either in acquisitions or mergers to avoid duplication of investments and capture larger market share at global place. Table 2.7 shows the data of number of overseas acquisitions by Indian pharmaceutical Industry. We can conclude that the year 2005 witnessed the maximum number of overseas acquisition due to paradigm change in pharmaceutical policies and enactment of certain new laws which are later discussed in this chapter. Indian companies had gained a lot by these cross border acquisitions and details of which has been given in table 2.8 Many Indian companies are seeking to expand their distinctive capabilities by acquiring specific skills, knowledge and technology abroad that are either unavailable or of inadequate quality at home. By mergers and acquisitions they get advantage of acquiring new resources and gain entry to new markets for better profitability. Table2.8 shows the number of cross border acquisitions by Indian companies with their focus areas. 2.7 INDIAN PHARMACEUTICAL MARKET AND THE WORLD : DISCUSSION The period between 2000 and 2010 witnessed Indias top 10drug companies growing in their sales turnovers, ranging between Rs 500-Rs 800 crore, top professionally-run MNC generics manufacturing companies with turnovers ranging from Rs3,500 crore to over Rs 7,000 crore. India is among the top 20 pharmaceutical exporters world-wide. Most of these exporting firms earlier depended on bulk drug supplies, small exports to unregulated markets in Africa and Asia and formulation sales in the domestic market, the last 10years saw them aggressively tapping regulated markets of the US and Europe and penetrating into newer and emerging markets. The Indian industry had filed only 3 marketing applications with the USFDA in 1998, the number swelled to 148 in 2009. Approximately $123bn of generic products is at risk (subject to patent renewal approvals by regulators) of losing patents by 2012.Even at a conservative estimate of 15% opportunity this translates into $18.4bn opportunity for India. However the figures need to be appropriately deflated since Indian opportunity will lie in generics equivalent of branded drugs, which would be cheaper. Ageing populations of the US (plus the 2010 US Healthcare Reforms in action), China European economies leading to the more and more expenditure on medicines and appreciation in the per capita consumption value of the drug products with cheaper rates. As global markets such as North America, Europe and Japan continue to slow down (graphical representation below), pharmaceutical companies are scanning markets for new growth opportunities to boost drug discovery potential, reduce time to market and squeeze costs along the value chain. The Industry is beginning to realize that some of the most promising opportunities will come from emerging markets (Asia/Australia/Africa Latin America). IMSHealth and other sources suggest that emerging markets (China, India, Brazil, Russia, Turkey, Mexico and South Korea) will contribute to over 40% of the incremental growth of the global Pharmaceutical industry over the next decade. With its enormous advantage ,including a large well educated ,skilled and English speaking workforce, low operational costs and improving regulatory infrastructure, India has the potential to become the regions hub for pharmaceutical and biotechnology discovery research, manufacturing, exporting and health care services within the next decade. However, in order for this to happen, it is imperative that the regulatory environment continues to improve . otherwise ,India will have to face tough competition from china leading to capture of market shares by china as their government strong commitment and pro industry policies have produced a favorable and protective environment for not only product patent but also for crucial data protection so while developing an Indian collaborative RD strategy, pharmaceutical MNCs should keep in mind certain issues like data and IP security, performance metrics, and quality standards, and address and evaluate these upfront to ensure a successful relati onship. Although the major factor that has increased the confidence of foreign multinationals looking for local opportunities in India is the adoption of a new product patent regime in January 2005. This already had facilitated concurrent global phase II and III clinical trials. A new patent regime has changed the dynamics of the Indian pharmaceuticals industry in other respects, too. Several leading domestic producers have begun to conduct original research into new chemical entities (NCEs) and novel drug delivery systems. However, these companies are likely to license most of these drug candidates to Western pharmaceutical companies, because few Indian companies can afford the high costs and failure rates associated with developing an NCE. In this context, several Indian firms have already entered into research partnerships with multinationals. Some pharmaceutical MNCs like AstraZeneca have opened their own captive research centers in India to take advantage of the low costs as we ll as availability of high quality intellectual work force. Russia 2013, marketing insight estimates. (ASSOCHAM). IMS estimates the healthcare market in India at $31.59 bn. by 2020, whereas the global management consulting major, McKinsey Co. predicts that the Indian pharmaceutical market is expected to touch $40 by 2015. The industry has given employment to approximately 2.86 mn people and has around 20,053 units. Globally, India is 4th in terms of volume (8% of worlds production), 13th in terms of value, and 17th in terms of pharmaceutical export value. The drugs and pharmaceuticals exported are worth over $3.8 bn. Section-III INDIAN PHARMACEUTICAL MARKET 2.8 DOMESTIC PHARMACEUTICAL MARKET The pharmaceutical industry in India meets around 70% of the countrys demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectibles. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical-formulations. As discussed in earlier chapters about the Indian Pharmaceutical sector which is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. North Indian states UTs are also engaged in production of pharmaceutical products, few states like Himachal Pradesh, Uttaranchal, are also providing tax holidays so as to motivate the pharma companies to enhance their production facilities, more over the climatic conditions and other macro factors are suitable for the growth of pharma and especially biotech., Industries in these two states. Table2.14 shows the state wise distribution in north India. FiG.-2.6 :STATE- WISE DISTRIBUTION OF PHARMACEUTICAL SECTOR IN INDIA, 2010-11 . graph3.JPG Source: Annual report: 201

The Character of Marek Shimerda in My Antonia :: My Antonia Essays

The Character of Marek Shimerda in My Antonia      Ã‚  Ã‚   In Willa Cather's novel, My Antonia, Marek Shimerda is starved for attention because he is constantly ignored due to his mental retardation. It is solely because of his handicap and the assumption of his inability to help out with the farming and household chores that his family views him as helpless which results in Marek's strange and awkward actions. He is presented as an ill minded young man throughout the novel, repeatedly excused, and resides in the shadow of his healthy, fully functional older brother, Ambrosh Shimerda.    Marek is a token character that is simply taken for granted. He is portrayed as strange and useless. When Jim Burden and his family first meet the Bohemians, he is approached by Marek, the second eldest son. "As he approached us, he began to make uncouth noises, and held up his hands to show us his fingers, which were webbed to the first knuckle, like a duck's foot. When he saw me draw back, he began to crow delightedly" (Cather, 24). Everyone who encounters this poor boy instantly views him as `crazy'. All of his actions are presented as strange. "The crazy boy, seeing the food, began to make soft, gurgling noises and stroked his stomach" (Cather, 60), and evidently he is. "The crazy boy went with them [outside], because he did not feel the cold. I believed he felt the cold as much as any one else, but he liked to be thought insensible to it. He was always coveting distinction, poor Marek" (Cather, 82)!    Because of everyone's inability to understand and relate to Marek, he is pitied and constantly excused. After Jim`s reaction to Marek`s webbed fingers, Marek begins to express himself, maybe even trying to communicate with what could be a new friend, but he is immediately quieted. ""Hoo, hoo-hoo, hoo-hoo!" like a rooster. His mother scowled and said sternly, "Marek!" then spoke rapidly to Krajiek in Bohemian. "She wants me to tell you he won't hurt anybody, Mrs. Burden. He was born like that..." No one bothers to befriend this young man or even tries to talk to him throughout the entire book. Although he is obviously mentally challenged, it is not evident that any one of the characters in Cather's novel tries to reach out to this young man or teach him to be a helpful resource around the Shimerdas' household.

Mass Extinction Essay -- K-T Extinction

ABSTRACT Several mass extinctions have occurred during the Earth’s history. The Cretaceous – Tertiary Boundary (K-T) Extinction caused the loss of at least three-quarters of all species known at that time including the dinosaurs. The cause of this mass extinction is a controversial subject among scientists but the fossil evidence of it’s occurrence is abundant. INTRODUCTION The K-T Extinction occurred 65 million years ago. Many species perished in that extinction. Today evidence for this extinction can be seen in the fossil record. Biological, botanical and geological evidence at the Cretaceous – Tertiary Boundary show that some enormous event occurred that caused mass extinction of life on the Earth. Controversy about the cause of the K-T extinction exists with two main theories currently being in favour. One theory is called Intrinsic Gradualism and believes the cause of the K-T Extinction was a slow and gradual Earth generated event, caused by intense volcanic activity and the effect of plate tectonics. The second theory is known as Extrinsic Catastrophism and proposes that the K-T Extinction was caused by a sudden and violent catastrophic event such as the Earth being struck by a meteor or asteroid. The K-T Extinction supports the concept of Punctuated Equilibrium in evolution because surviving species evolved and others were exterminated. Th is creates the stepladder effect of evolution seen in the fossil record . THE K-T EXTINCTION The Cretaceous period occurred between 144 and 65 million years ago. The K-T Extinction is an event that happened at the end of this period 65 million years ago. By the beginning of the Tertiary period eighty-five percent of all species disappeared, making it the second largest mass extinction event in geological history (â€Å"The End-Cretaceous (K-T) Extinction†, accessed 2000). Among the species that perished were the dinosaurs, pterosaurs, belemnoids, many species of plants, except ferns and seed-producing plants, ammonoids, marine reptiles and rudist bivalves. Severely affected organisms included planktic foraminifera, calcareous nannnoplankton, diatoms, dinoflagellates, brachiopods, mollusca, echinoids and fish. Mammals, birds, turtles, crocodiles, lizards, snakes and amphibians fared much better and were mostly unaffected by the End-Cretaceous mass extinction (â€Å"The End-cretaceous (K-T) Extinction†, accessed 2000... ...pdated 1995, accessed 3 Sept. 2000), Dino Buzz – What killed The Dinosaurs ? – Current Arguments, http://www.ucmp.berkeley.edu/diapsids/extinctheory.html Lowood, H. 1998 (updated 7 Sept 1999, accessed 30 June 2000), Stanford Presidential Lectures and Symposia in the Humanities and Arts, Stephen Jay Gould, http: //prelectur.stanford.edu/lecturers/gould/index.html Smith, P.L. 1997a (updated 1997, accessed 3 Sept. 2000), Biological Evidence, http://www.science.ubc.ca/~geol313/lecture/kt/biol/biol.htm Smith, P.L. 1997b (updated 1997, accessed 3 Sept. 2000), The Marine Realm, http://www.science.ubc.ca/~geol313/lecture/kt/biol/marine/marine.htm Smith, P.L. 1997c (updated 1997, accessed 3 Sept. 2000), The Terrestrial Realm, http://www.science.ubc.ca/~geol313/lecture/kt/biol/terres/terres.htm Smith, P.L. 1997d (updated 1997, accessed 3 Sept. 2000), Geological Evidence, http://www.science.ubc.ca/~geol313/lecture/kt/geol/geol.htm â€Å"Speculated Causes of the End-Cretaceous Extinction† (accessed 3 Sept. 2000), http://www.wf.carleton.ca/Museum/cretcause.htm â€Å"The End-Cretaceous (K-T) Extinction† (accessed 3 Sept. 2000), http://www.wf.carleton.ca/Museum/cretmass.htm

Racing Neighbors Cause Crashing Communities Essay

Many neighborhoods face serious community problems because of certain factors and they have a certain effect on the people living in the communities. I live around a community where there are a lot of car street races which happen on a regular basis and it creates major chaos over the weekends. Seems like it is not a major issue, however, these street races cause major trouble to all the neighbors as it creates noise, causes accidents, creates trouble for all the stores around, for people travelling at night and so on. Every weekend, a specific parking lot in the town of Farmingdale is filled with Hot Rods, college students, high school students and even adults, not to mention, cops too. This is a huge parking lot outside a mall which has plenty of room for cars and is connected to a highway-route 110. It is the main attraction for guys and girls with hot rods. I heard a lot of stories about this location and about the races taking place there every weekend so I decided to take a look for myself before I could believe any of this. One night, I made a trip to this famous parking lot! At first, when I got to the parking lot, all I saw was a few random cars parked with some guys standing around them and talking to each other in groups. I parked my car there and stopped to watch what happens. I was extremely curious because I had only heard of these kind of scenes in movies and never thought it would be the reality. A little after 11pm, a group of cars came into the parking lot with extremely loud exhaust pipes and loud music. As they revved up the engines my adrenaline started pumping. I could not believe what my eyes saw. A large number of cars drove in and parked there. There were people of all different age groups coming in from high school students, to college students and even elderly men around the age of forty who wanted to show off their hot rods. Soon after, some drivers including female drives took their cars out into the driveway and started drifting and performing rolling burnouts to get the crowd excited. I stepped out of my car and stood there to watc h. These people were enjoying themselves with loud music, alcohol, dancing with girls and screaming and shouting. I was shocked when a few high school kids approached me to ask me  about my car because these kids were 9th graders who had sneaked out of their houses at midnight with their parents cars for these races. After around half an hour, a group of cars revved up their engines and started moving towards route 110 so I decided to follow. Once we got onto route 110 they start driving like crazy people over speeding and cutting lanes and eventually turned onto a street off route 110. This lane was completely isolated and there were barely any cars parked there so they lined up their cars there and made a roadblock at the two ends of the lane and started having drag races which made a lot of sound and obviously called in for cops. This is where the major problems from these races start. Once the cops come in, chaos occurs. These guys get into their cars and started racing off from these race sites in all different directions to avoid getting caught. They go onto the main roads and over speed causing accidents not only for themselves but even other innocent people. They also disturb so many people’s sleep at night with all the noise they create. They get into accidents, get caught and pay fines, cause trouble to other drivers on the road and so on. This is a major community problem as it attracts a lot of students in the community from not only colleges but also high schools. These kids have illegal modifications on their cars which adds to money in the black market. It also encourages many others to join this racing league which leads to accidents and deaths. There is a lot of illegal betting and gambling, underage drinking, over speeding and many such laws broken which cause serious community problems every weekend and according to me this should be checked and stopped as soon as possible!

Critique of Alexander Pope by Carole Fabricante Essay

â€Å"Defining Self and Others: Pope and Eighteenth Century Gender Ideology† – Carole Fabricante. This is an in depth critique by Carole Fabricante of eighteenth century gender ideologies in which Fabricante uses the poet Alexander Pope’s poetry as an example of changing thoughts towards gender roles. In particular, or as a specific argument, Fabricante warns about the use of ‘active voices’ to relate the situations, circumstances and feelings of the ‘passive’. Herein she discusses the dangers of allowing others who attempt to empathise with the voiceless, to become the main petition for the said people. The eighteenth century being a time in which women were largely relegated to the ‘seen and not heard’ caste, Fabricante examines Pope’s position not only as a protagonist for the ‘unspoken’, but also as devils advocate. She describes Pope’s own history as a crippled and deformed individual whose own identity is compromised by his inability to conform to the socialized standards of masculinity. This would naturally grant Pope a greater ability to empathize with the underdog. â€Å"Deformed, dwarfish, sickly, and probably impotent as a result of having contracted spinal tuberculosis in infancy, Pope was someone whose â€Å"manhood† was continually being called into question both by his enemies in print and by the women in his life, not to mention by his own ironic perceptions of himself. † (Fabricante). As a result of his own deformity, Fabricante asserts that his own idea of patriarchal power hierarchy and that this may at some level give him a greater lease to speak for those who ‘cannot’. Pope is by no means a passive voice, although speaking as a women in poems such as â€Å"Eloisa to Abelard† and â€Å"Epistle to Miss Blount†, Fabricante does question whether Pope uses a form of political satire to direct is ideas. However Fabricante does admit the following: â€Å"Pope’s ambiguous and contradictory position in society affords us the opportunity to explore the dialectical interaction between the voices of marginality and dominance as these vye, not only among different groups in society, but also within a single personality and consciousness. †(Fabricante). The paper as a whole questions the usage over time of writers, artists and activists in order to speak for others, believing that this is not a clear or authentic view of those individuals. She compares Pope’s representation of women to that of Swift, another eighteenth century poet. In this comparison she examines the subtlety with which Pope describes women as a victim of choice-less marriages and breeding stock as opposed to Swifts considerably less authentic identification. She also explores the use of objectification of women as an entity for which the primary necessity it fulfils, are men. As an exploratory paper, Fabricante does touch on a great deal of the effects of subjugation of women as the ‘other’ over time. This is particularly important in an era such as the eighteenth century where the socialized acceptance by women of their fate, was beginning to disintegrate. Following the Renaissance, reading the likes of Shakespeares Othello and Romeo and Juliet, the discomfort faced by women was already rearing its head. However, it took centuries for this transformation to come into fruition. I feel that at times Fabricante attacks the wrong people though. In the beginning her main focus is on the Foucauldian perception of the voiceless being incarcerated by those intent on speaking for them. In many ways this practice does rob the recipient even further of their own right to be heard, however, those who can identify say for instance with abortion, may not be able to speak for themselves. This leads in the end, to no one getting anywhere. The point, I believe of people speaking for others, is not to precipitate further oppression, but to give them the strength to speak for themselves. Foucault, as Fabricante uses for an example, was himself a minority, being outwardly gay and questioning the idea of transgression as perceived by society, makes a good representation of those previously voiceless speaking out. As a sociological argument, Fabricante is eloquent and aggressive and may strike the reader as being decidedly feminist, although this may be a misconception on the part of the reader. Fabricante makes many interesting and pertinent points although she is not easy to read. For this reason it necessary to remember that the paper is not a poetic analysis, but a personality one. In the greater scheme of social theory, Fabricante displays all the downfalls and assets of social study particularly that of the need to label people as ‘other’. Describing another group or individual as ‘other’ is a social truth, as all things that can be defined, must by all intents and purposes possess an opposite. I believe Fabricante’s dissertation to be insightful, if at times a little aggressive. The paper sometimes appeared a little confused, perhaps because she uses a number of external which are placed within her own ideas.